Date of submission: 27/05/2022

Pancreatic Carcinoma

TM00176

Model characterisation

Provided by

The Jackson laboratory

View data at Contact JAX

License: EMBL-EBI

Patient / Tumour Metadata

Patient Sex
male
Patient Age
Not Provided
Patient Ethnicity
Not Hispanic Or Latino
Tumour Type
Metastatic
Cancer Grade
Not provided
Cancer Stage
AJCC IV
Primary Site
pancreas
Collection Site
pancreas

PDX model engraftment

PDX model engraftment
HOST STRAIN NAME	SITE	TYPE	MATERIAL	MATERIAL STATUS	PASSAGE
nsg	Not Provided	Heterotopic	Core Needle Biopsy	Not Provided	1

Model quality control

Model quality control
TECHNIQUE	DESCRIPTION	PASSAGE
Histology, Ki67 Ihc, Cd45 Ihc, Str Analysis	The histology of the engrafted tumor retains morphologic features of the primary patient tumor as assessed by a Board Certified Pathologist. IHC for human Ki67 validates that the tumor cells are actively dividing and are of human origin. IHC for CD45 and cytokeratin (AE1/AE3) rules out a xenograft-associated lymphocytic tumor. STR analysis validates provenance of engrafted tumor.	Not provided

Immune markers

Immune markers
SAMPLE ID	MMR	MSI	Mutations per mb	TMB	Ploidy
PA0165F629P0000P1011P2	Not provided	Stable	Not provided	5.66	Not provided

Model treatment

Model treatment
DRUG	DOSE	PASSAGE	RESPONSE
Gemcitabine ChEMBL PubChem	150.0 mg/kg	1	Partial Response
Cisplatin ChEMBL PubChem	2.0 mg/kg	1	Progressive Disease
Fluorouracil ChEMBL PubChem	30.0 mg/kg	1	Progressive Disease
Dextrose Monohydrate PubChem	5.0 ml/kg	1	Progressive Disease